
Linus Backert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3048861/publications.pdf Version: 2024-02-01



LINUS RACKEDT

#	Article	IF	CITATIONS
1	Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet, The, 2017, 390, 1511-1520.	13.7	350
2	Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Medicine, 2015, 7, 119.	8.2	178
3	The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9942-E9951.	7.1	152
4	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E166-75.	7.1	150
5	HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. , 2021, 9, e002071.		126
6	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy. Blood, 2015, 126, 1203-1213.	1.4	103
7	Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. Journal of Immunology, 2017, 199, 2639-2651.	0.8	81
8	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.9	56
9	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncolmmunology, 2018, 7, e1316438.	4.6	42
10	A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. , 2019, 7, 307.		39
11	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathologica, 2018, 135, 923-938.	7.7	36
12	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Medicine, 2020, 12, 32.	8.2	32
13	Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS ONE, 2016, 11, e0167017.	2.5	17
14	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia―antigens. Oncotarget, 2017, 8, 43915-43924.	1.8	12
15	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leukemia and Lymphoma, 2018, 59, 1949-1958.	1.3	4
16	Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers. Blood, 2015, 126, 1722-1722.	1.4	0